Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded by UBS Group to “Neutral”

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by research analysts at UBS Group from a “buy” rating to a “neutral” rating in a research report issued on Thursday, MarketBeat.com reports. They currently have a $738.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $1,130.00. UBS Group’s price objective points to a potential upside of 8.28% from the stock’s previous close.

REGN has been the subject of a number of other reports. Sanford C. Bernstein reduced their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Citigroup reduced their price target on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a research report on Tuesday. Royal Bank of Canada cut their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Leerink Partners restated a “market perform” rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $681.58 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a 50-day moving average of $741.54 and a 200-day moving average of $952.59. The company has a market cap of $74.90 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10. Regeneron Pharmaceuticals has a one year low of $666.25 and a one year high of $1,211.20.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Mercer Global Advisors Inc. ADV raised its stake in shares of Regeneron Pharmaceuticals by 4.8% during the second quarter. Mercer Global Advisors Inc. ADV now owns 24,319 shares of the biopharmaceutical company’s stock valued at $25,479,000 after acquiring an additional 1,122 shares during the last quarter. Argent Trust Co raised its position in Regeneron Pharmaceuticals by 1.3% during the 2nd quarter. Argent Trust Co now owns 2,370 shares of the biopharmaceutical company’s stock worth $2,491,000 after purchasing an additional 31 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. lifted its holdings in Regeneron Pharmaceuticals by 5.4% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,314 shares of the biopharmaceutical company’s stock worth $2,432,000 after buying an additional 119 shares during the period. MRP Capital Investments LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $306,000. Finally, Mark Sheptoff Financial Planning LLC raised its position in shares of Regeneron Pharmaceuticals by 35.0% during the second quarter. Mark Sheptoff Financial Planning LLC now owns 135 shares of the biopharmaceutical company’s stock worth $142,000 after acquiring an additional 35 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.